Zofran Birth Defect MDL Subject Of Oct. 1 Hearing
(August 18, 2015, 2:02 PM EDT) -- WASHINGTON, D.C. — A federal judicial panel on Aug. 14 said it will hear arguments on Oct. 1 on centralizing 12 federal lawsuits in which plaintiffs claim that the prescription nausea drug Zofran causes birth defects (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, JPMDL).
The motion before the Judicial Panel on Multidistrict Litigation was filed July 6 by defendant GlaxoSmithKline LLC (GSK). GSK suggests that an MDL be created in the U.S. District Court for the Eastern District of Pennsylvania and assigned...